Pharmacology Quiz: Antiplatelet Drugs
20 questions · exam conditions
0:00
Antiplatelet DrugsQuestion 1 of 20

A 66-year-old male on DAPT (aspirin and clopidogrel) for a stent placed 1 year ago presents after a fall, and a CT scan reveals a small traumatic intracranial hemorrhage (ICH). He is conscious and his neurological exam is stable.

What is the most critical and immediate step in managing his antiplatelet therapy to prevent hematoma expansion?

Administer a loading dose of ticagrelor to achieve more predictable platelet inhibition.
Administer desmopressin (DDAVP) to enhance endogenous factor VIII release.
Arrange for urgent platelet transfusion.
Continue current antiplatelet therapy to prevent acute stent thrombosis.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Antiplatelet Drugs

Practice Antiplatelet Drugs in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Antiplatelet Drugs, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 66-year-old male on DAPT (aspirin and clopidogrel) for a stent placed 1 year ago presents after a fall, and a CT scan reveals a small traumatic intracranial hemorrhage (ICH). He is conscious and his neurological exam is stable.

What is the most critical and immediate step in managing his antiplatelet therapy to prevent hematoma expansion?

  1. Administer a loading dose of ticagrelor to achieve more predictable platelet inhibition.
  2. Administer desmopressin (DDAVP) to enhance endogenous factor VIII release.
  3. Arrange for urgent platelet transfusion. (correct answer)
  4. Continue current antiplatelet therapy to prevent acute stent thrombosis.
Explanation: In the setting of a life-threatening bleed such as an intracranial hemorrhage, the risk of hematoma expansion far outweighs the risk of stent thrombosis (especially >1 year post-PCI). The immediate priority is to restore hemostasis. Platelet transfusion is the primary intervention to provide functional platelets, although its efficacy is limited by the presence of irreversible inhibitors like clopidogrel. Despite this limitation, it is the most direct and recommended therapy. Desmopressin may be considered as an adjunct but is not the primary intervention. Continuing antiplatelet agents (D) or switching them (A) would be catastrophic.

Question 2

A 72-year-old female is prescribed clopidogrel following a percutaneous coronary intervention (PCI). Her past medical history is significant for gastroesophageal reflux disease (GERD), for which she takes a daily proton pump inhibitor (PPI). The pharmacist notes a potential drug-drug interaction that could reduce the efficacy of her antiplatelet therapy.

The interaction of concern is most significant with which of the following medications?

  1. Famotidine
  2. Pantoprazole
  3. Omeprazole (correct answer)
  4. Calcium carbonate
Explanation: Clopidogrel is a prodrug that requires activation by the cytochrome P450 enzyme CYP2C19. Omeprazole (and its S-enantiomer, esomeprazole) is a potent inhibitor of CYP2C19, which can significantly reduce the conversion of clopidogrel to its active metabolite, thereby decreasing its antiplatelet effect and potentially leading to treatment failure (e.g., stent thrombosis). Pantoprazole is a much weaker inhibitor of CYP2C19 and is generally considered a safer alternative in this context. Famotidine (an H2-receptor antagonist) and calcium carbonate (an antacid) do not significantly interact with CYP2C19.

Question 3

A 62-year-old male on long-term DAPT with aspirin and ticagrelor presents for a follow-up visit. He reports a new, persistent, and bothersome shortness of breath that started a few weeks after initiating ticagrelor. A cardiac and pulmonary workup, including chest X-ray and ECG, is unremarkable.

What is the most likely explanation for this patient's dyspnea?

  1. It is an early sign of a ticagrelor-induced interstitial lung disease.
  2. It is a known, non-hypoxic adverse effect of ticagrelor, likely related to adenosine metabolism. (correct answer)
  3. It is a symptom of micro-bleeding into the pulmonary alveoli, a complication of DAPT.
  4. It reflects decreased oxygen-carrying capacity due to chronic, occult gastrointestinal blood loss.
Explanation: Dyspnea is a well-documented and relatively common side effect of ticagrelor, occurring in 10-15% of patients. It is typically mild to moderate, occurs early in therapy, and often resolves on its own. The mechanism is not fully elucidated but is thought to be related to ticagrelor's inhibition of adenosine reuptake by red blood cells, leading to increased local adenosine levels which can stimulate pulmonary chemoreceptors. Importantly, this dyspnea is not associated with hypoxia or changes in lung function. While bleeding (C, D) is a risk of DAPT, this specific presentation without evidence of anemia or lung pathology points to the known pharmacological side effect of the drug itself.

Question 4

Ticagrelor and clopidogrel both ultimately lead to inhibition of the platelet P2Y12 receptor. However, their pharmacokinetic and pharmacodynamic profiles differ significantly. Which of the following statements correctly identifies a key difference that influences their clinical effects?

  1. Ticagrelor is a prodrug that undergoes extensive first-pass metabolism, while clopidogrel is an active drug.
  2. Clopidogrel binds reversibly to the P2Y12 receptor, allowing for faster offset of action compared to ticagrelor.
  3. Ticagrelor and its active metabolite directly inhibit the P2Y12 receptor without requiring metabolic activation. (correct answer)
  4. Genetic polymorphisms in CYP2C19 have a greater impact on the antiplatelet effect of ticagrelor than on clopidogrel.
Explanation: A fundamental difference is that ticagrelor is an orally active drug that, along with its active metabolite, directly and reversibly binds to the P2Y12 receptor. It does not require hepatic metabolic activation to exert its effect. In contrast, clopidogrel (and prasugrel) is a prodrug that must be converted to an active metabolite in the liver. This difference explains ticagrelor's faster onset of action and more consistent platelet inhibition, as it bypasses the need for the often-variable CYP enzyme system. Consequently, CYP2C19 polymorphisms primarily affect clopidogrel, not ticagrelor (D is incorrect). A and B reverse the properties of the two drugs.

Question 5

An 82-year-old female (weight 52 kg) with an estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73m² and a history of a bleeding peptic ulcer 5 years ago is started on DAPT with aspirin and ticagrelor after an NSTEMI.

Which combination of factors places this patient at the highest intrinsic risk for a major bleed, independent of the antiplatelet agents prescribed?

  1. Advanced age, female sex, and low body weight.
  2. History of peptic ulcer disease and moderate chronic kidney disease (CKD).
  3. Low body weight and moderate chronic kidney disease (CKD).
  4. Advanced age and moderate chronic kidney disease (CKD). (correct answer)
Explanation: While all listed factors contribute to bleeding risk, advanced age and chronic kidney disease are consistently identified as two of the strongest independent predictors of major bleeding in patients on antiplatelet therapy. CKD impairs platelet function (uremic platelet dysfunction) and drug clearance, while advanced age is associated with comorbidities and vascular fragility. Although a history of prior bleeding (like a peptic ulcer) is a major risk factor, the combination of age and CKD often represents a more profound and systemic increase in bleeding propensity. Low body weight is a risk factor, particularly for prasugrel dosing, but age and CKD are more globally significant.

Question 6

A 65-year-old male with a drug-eluting stent placed 4 months ago for an acute coronary syndrome (ACS) is maintained on dual antiplatelet therapy (DAPT) with aspirin 81 mg and clopidogrel 75 mg daily. He presents with acute cholecystitis requiring cholecystectomy within the next few days. The surgical team is concerned about perioperative bleeding.

Considering his high risk for stent thrombosis, which of the following is the most appropriate strategy for managing his antiplatelet therapy?

  1. Discontinue both aspirin and clopidogrel 7 days before surgery to minimize bleeding risk.
  2. Continue both aspirin and clopidogrel through the perioperative period to prevent stent thrombosis.
  3. Continue aspirin and discontinue clopidogrel 5 days before surgery, restarting it as soon as safely possible post-operatively. (correct answer)
  4. Switch clopidogrel to ticagrelor immediately and continue DAPT until the morning of surgery.
Explanation: The correct approach balances the high risk of stent thrombosis (especially within 6 months of placement) against the surgical bleeding risk. Continuing aspirin monotherapy provides a baseline level of antiplatelet effect, mitigating some thrombotic risk. Discontinuing the P2Y12 inhibitor, clopidogrel, for 5 days allows for partial recovery of platelet function, as its effect is irreversible and lasts for the life of the platelet. This is the standard recommendation for balancing these competing risks.

Question 7

A patient who had a coronary stent placed two years ago has been stable on aspirin 81 mg daily. He is now being considered for an elective inguinal hernia repair. The surgeon requests that all antiplatelet medications be stopped 7 days prior to the procedure.

What is the most accurate assessment of the thrombotic versus bleeding risk in this patient?

  1. The risk of stent thrombosis is still very high, and aspirin must be continued perioperatively.
  2. The risk of bleeding on aspirin monotherapy is minimal and does not warrant discontinuation for this type of surgery.
  3. The risk of stent thrombosis is now relatively low, and briefly holding aspirin is acceptable for a procedure with moderate bleeding risk. (correct answer)
  4. The patient should be transitioned to a short-acting P2Y12 inhibitor like ticagrelor to bridge the perioperative period.
Explanation: The risk of stent thrombosis is highest in the first few months after placement and decreases significantly over time. After two years, the risk of an acute thrombosis from briefly holding aspirin for a few days is low. Inguinal hernia repair has a moderate bleeding risk, and continuing aspirin can increase the incidence of wound hematoma and other bleeding complications. Therefore, in this stable, low-risk thrombotic scenario, it is generally considered safe and appropriate to temporarily discontinue aspirin to optimize the surgical field. Bridging therapy (D) is not indicated for aspirin monotherapy in a low-risk patient.

Question 8

A patient on dual antiplatelet therapy develops significant gingival bleeding after dental cleaning. Their physician attributes this to the irreversible inhibition of platelet aggregation. Which molecule's synthesis is most directly and lastingly blocked by aspirin, leading to this effect?

  1. Prostacyclin (PGI₂)
  2. Thromboxane A₂ (TXA₂) (correct answer)
  3. Leukotriene B₄
  4. Adenosine diphosphate (ADP)
Explanation: Aspirin exerts its antiplatelet effect by irreversibly acetylating and inactivating cyclooxygenase-1 (COX-1). Within the platelet, COX-1 is the critical enzyme for converting arachidonic acid into prostaglandin H₂, which is then converted by thromboxane synthase into Thromboxane A₂ (TXA₂). TXA₂ is a potent vasoconstrictor and a powerful promoter of platelet aggregation. By blocking TXA₂ synthesis for the life of the platelet, aspirin reduces platelet aggregation and increases bleeding time. Prostacyclin (PGI₂) is an inhibitor of aggregation produced by endothelial cells. Leukotrienes are synthesized via the lipoxygenase pathway. ADP is released from platelet dense granules and is the target of P2Y12 inhibitors, not aspirin.

Question 9

A patient who had a coronary stent placed two years ago has been stable on aspirin 81 mg daily. He is now being considered for an elective inguinal hernia repair. The surgeon requests that all antiplatelet medications be stopped 7 days prior to the procedure.

What is the most accurate assessment of the thrombotic versus bleeding risk in this patient?

  1. The risk of stent thrombosis is still very high, and aspirin must be continued perioperatively.
  2. The risk of bleeding on aspirin monotherapy is minimal and does not warrant discontinuation for this type of surgery.
  3. The risk of stent thrombosis is now relatively low, and briefly holding aspirin is acceptable for a procedure with moderate bleeding risk. (correct answer)
  4. The patient should be transitioned to a short-acting P2Y12 inhibitor like ticagrelor to bridge the perioperative period.
Explanation: The risk of stent thrombosis is highest in the first few months after placement and decreases significantly over time. After two years, the risk of an acute thrombosis from briefly holding aspirin for a few days is low. Inguinal hernia repair has a moderate bleeding risk, and continuing aspirin can increase the incidence of wound hematoma and other bleeding complications. Therefore, in this stable, low-risk thrombotic scenario, it is generally considered safe and appropriate to temporarily discontinue aspirin to optimize the surgical field. Bridging therapy (D) is not indicated for aspirin monotherapy in a low-risk patient.

Question 10

A 68-year-old male on aspirin and ticagrelor for a recent non-ST-elevation myocardial infarction (NSTEMI) presents to the emergency department with hematemesis and melena. He is hypotensive and tachycardic. Endoscopy is planned, but he continues to have active, significant bleeding.

In addition to hemodynamic support and PPI infusion, which intervention is most likely to acutely improve hemostasis by counteracting the effects of ticagrelor?

  1. Administration of intravenous vitamin K.
  2. Infusion of protamine sulfate.
  3. Transfusion of platelets. (correct answer)
  4. Administration of desmopressin (DDAVP).
Explanation: Ticagrelor is a reversible P2Y12 receptor inhibitor. Because it reversibly binds to the receptor, there is an equilibrium between bound and unbound drug in the plasma. Transfusing fresh, drug-naive platelets provides a new pool of functional P2Y12 receptors that can participate in hemostasis. While some transfused platelets may become inhibited, the overall effect is an increase in functional platelet mass. This is in contrast to irreversible inhibitors (clopidogrel, prasugrel), where circulating active metabolite will irreversibly inhibit the transfused platelets, rendering transfusion less effective. Vitamin K reverses warfarin, protamine sulfate reverses heparin, and DDAVP is used for specific platelet function disorders (e.g., uremia) but is not a direct reversal agent for P2Y12 inhibitors.

Question 11

Low-dose aspirin (81 mg) irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets. How does this selective action lead to a net anti-thrombotic effect despite also affecting vascular endothelial cells?

  1. Endothelial cells primarily use COX-2 to produce prostacyclin, an enzyme which is not affected by low-dose aspirin.
  2. Aspirin is rapidly cleared from the circulation, but because platelets are anucleate, they cannot regenerate COX-1 for their lifespan. (correct answer)
  3. Platelets concentrate aspirin intracellularly to a much greater degree than endothelial cells, resulting in a selective effect.
  4. Systemic circulation delivers aspirin primarily to the portal vein, where it acetylates platelets before being metabolized by the liver.
Explanation: The key to aspirin's antiplatelet effect at low doses is the difference in protein synthesis capability between platelets and endothelial cells. Aspirin irreversibly acetylates COX-1 in both cell types. However, platelets are anucleate and cannot synthesize new enzyme, so the inhibition lasts for the platelet's entire 7-10 day lifespan. In contrast, nucleated endothelial cells can rapidly synthesize new COX-1, restoring their production of prostacyclin (PGI2, an inhibitor of platelet aggregation). This differential recovery leads to a sustained deficit in platelet thromboxane A2 (TXA2, a potent aggregator) relative to endothelial PGI2, tipping the balance toward anti-aggregation. The presystemic effect in the portal circulation (D) contributes, but the anucleate nature of platelets is the primary reason for the sustained effect.

Question 12

A 76-year-old male with a history of a transient ischemic attack (TIA) 2 years ago is admitted with an acute ST-elevation myocardial infarction (STEMI) and undergoes primary PCI with stenting. The physician is choosing a P2Y12 inhibitor to add to aspirin.

Which of the following P2Y12 inhibitors is contraindicated in this patient due to his medical history?

  1. Clopidogrel
  2. Ticagrelor
  3. Prasugrel (correct answer)
  4. Cangrelor
Explanation: Prasugrel is contraindicated in patients with a prior history of stroke or transient ischemic attack (TIA). Clinical trials (e.g., TRITON-TIMI 38) demonstrated that in this subgroup, prasugrel was associated with an increased risk of intracranial hemorrhage that outweighed its ischemic benefits. Clopidogrel and ticagrelor do not carry this specific contraindication and are appropriate options. Cangrelor is an intravenous agent used during PCI and not for long-term maintenance in this context.

Question 13

An 82-year-old female (weight 52 kg) with an estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73m² and a history of a bleeding peptic ulcer 5 years ago is started on DAPT with aspirin and ticagrelor after an NSTEMI.

Which combination of factors places this patient at the highest intrinsic risk for a major bleed, independent of the antiplatelet agents prescribed?

  1. Advanced age, female sex, and low body weight.
  2. History of peptic ulcer disease and moderate chronic kidney disease (CKD).
  3. Low body weight and moderate chronic kidney disease (CKD).
  4. Advanced age and moderate chronic kidney disease (CKD). (correct answer)
Explanation: While all listed factors contribute to bleeding risk, advanced age and chronic kidney disease are consistently identified as two of the strongest independent predictors of major bleeding in patients on antiplatelet therapy. CKD impairs platelet function (uremic platelet dysfunction) and drug clearance, while advanced age is associated with comorbidities and vascular fragility. Although a history of prior bleeding (like a peptic ulcer) is a major risk factor, the combination of age and CKD often represents a more profound and systemic increase in bleeding propensity. Low body weight is a risk factor, particularly for prasugrel dosing, but age and CKD are more globally significant.

Question 14

A patient on dual antiplatelet therapy develops significant gingival bleeding after dental cleaning. Their physician attributes this to the irreversible inhibition of platelet aggregation. Which molecule's synthesis is most directly and lastingly blocked by aspirin, leading to this effect?

  1. Prostacyclin (PGI₂)
  2. Thromboxane A₂ (TXA₂) (correct answer)
  3. Leukotriene B₄
  4. Adenosine diphosphate (ADP)
Explanation: Aspirin exerts its antiplatelet effect by irreversibly acetylating and inactivating cyclooxygenase-1 (COX-1). Within the platelet, COX-1 is the critical enzyme for converting arachidonic acid into prostaglandin H₂, which is then converted by thromboxane synthase into Thromboxane A₂ (TXA₂). TXA₂ is a potent vasoconstrictor and a powerful promoter of platelet aggregation. By blocking TXA₂ synthesis for the life of the platelet, aspirin reduces platelet aggregation and increases bleeding time. Prostacyclin (PGI₂) is an inhibitor of aggregation produced by endothelial cells. Leukotrienes are synthesized via the lipoxygenase pathway. ADP is released from platelet dense granules and is the target of P2Y12 inhibitors, not aspirin.

Question 15

A 62-year-old male on long-term DAPT with aspirin and ticagrelor presents for a follow-up visit. He reports a new, persistent, and bothersome shortness of breath that started a few weeks after initiating ticagrelor. A cardiac and pulmonary workup, including chest X-ray and ECG, is unremarkable.

What is the most likely explanation for this patient's dyspnea?

  1. It is an early sign of a ticagrelor-induced interstitial lung disease.
  2. It is a known, non-hypoxic adverse effect of ticagrelor, likely related to adenosine metabolism. (correct answer)
  3. It is a symptom of micro-bleeding into the pulmonary alveoli, a complication of DAPT.
  4. It reflects decreased oxygen-carrying capacity due to chronic, occult gastrointestinal blood loss.
Explanation: Dyspnea is a well-documented and relatively common side effect of ticagrelor, occurring in 10-15% of patients. It is typically mild to moderate, occurs early in therapy, and often resolves on its own. The mechanism is not fully elucidated but is thought to be related to ticagrelor's inhibition of adenosine reuptake by red blood cells, leading to increased local adenosine levels which can stimulate pulmonary chemoreceptors. Importantly, this dyspnea is not associated with hypoxia or changes in lung function. While bleeding (C, D) is a risk of DAPT, this specific presentation without evidence of anemia or lung pathology points to the known pharmacological side effect of the drug itself.

Question 16

An 80-year-old female weighing 48 kg requires a P2Y12 inhibitor after PCI for ACS. The medical team is concerned about her heightened bleeding risk due to her age and low body weight.

Which of the following represents the most appropriate evidence-based selection and dosing for a P2Y12 inhibitor in this patient?

  1. Prasugrel, at a reduced maintenance dose of 5 mg daily. (correct answer)
  2. Prasugrel, at the standard maintenance dose of 10 mg daily.
  3. Ticagrelor, at a reduced maintenance dose of 60 mg twice daily.
  4. Clopidogrel, at an increased maintenance dose of 150 mg daily.
Explanation: Prasugrel has specific dosing recommendations for certain populations to mitigate bleeding risk. For patients with a body weight <60 kg, a reduced maintenance dose of 5 mg daily is recommended instead of the standard 10 mg. While prasugrel should be used with caution in patients ≥75 years, if chosen, the dose reduction for low body weight is critical. Ticagrelor does not have a recommended dose adjustment for age or weight, and the 60 mg BID dose is for long-term therapy (>1 year after MI), not initial treatment. Increasing the clopidogrel dose would increase bleeding risk without a clear indication.

Question 17

A 66-year-old male on DAPT (aspirin and clopidogrel) for a stent placed 1 year ago presents after a fall, and a CT scan reveals a small traumatic intracranial hemorrhage (ICH). He is conscious and his neurological exam is stable.

What is the most critical and immediate step in managing his antiplatelet therapy to prevent hematoma expansion?

  1. Administer a loading dose of ticagrelor to achieve more predictable platelet inhibition.
  2. Administer desmopressin (DDAVP) to enhance endogenous factor VIII release.
  3. Arrange for urgent platelet transfusion. (correct answer)
  4. Continue current antiplatelet therapy to prevent acute stent thrombosis.
Explanation: In the setting of a life-threatening bleed such as an intracranial hemorrhage, the risk of hematoma expansion far outweighs the risk of stent thrombosis (especially >1 year post-PCI). The immediate priority is to restore hemostasis. Platelet transfusion is the primary intervention to provide functional platelets, although its efficacy is limited by the presence of irreversible inhibitors like clopidogrel. Despite this limitation, it is the most direct and recommended therapy. Desmopressin may be considered as an adjunct but is not the primary intervention. Continuing antiplatelet agents (D) or switching them (A) would be catastrophic.

Question 18

Aspirin 'resistance' is a term used to describe the occurrence of ischemic events in patients taking aspirin. While non-adherence is a major factor, several pharmacodynamic mechanisms have been proposed. Which of the following is the LEAST plausible biological mechanism for true aspirin resistance?

  1. Platelet activation through pathways that are not dependent on thromboxane A₂, such as thrombin or ADP-mediated pathways.
  2. Genetic polymorphisms in the cyclooxygenase-1 (COX-1) enzyme that prevent aspirin from binding and acetylating it.
  3. Rapid platelet turnover from the bone marrow, providing a daily cohort of new, uninhibited platelets.
  4. Induction of hepatic cytochrome P450 enzymes leading to accelerated metabolism and clearance of aspirin. (correct answer)
Explanation: Aspirin is rapidly deacetylated to salicylic acid by esterases in the gut wall, liver, and blood, not primarily by cytochrome P450 enzymes. Its antiplatelet effect is achieved during its first pass through the portal circulation. Therefore, induction of CYP450 enzymes is not a relevant mechanism for its clearance or for resistance to its antiplatelet effect. In contrast, increased platelet activation via non-TXA₂ pathways (A), genetic variants of COX-1 (B), and high platelet turnover (C) are all recognized and plausible biological mechanisms that can overcome the antiplatelet effect of aspirin, contributing to the phenomenon of 'aspirin resistance'.

Question 19

A 72-year-old female is prescribed clopidogrel following a percutaneous coronary intervention (PCI). Her past medical history is significant for gastroesophageal reflux disease (GERD), for which she takes a daily proton pump inhibitor (PPI). The pharmacist notes a potential drug-drug interaction that could reduce the efficacy of her antiplatelet therapy.

The interaction of concern is most significant with which of the following medications?

  1. Famotidine
  2. Pantoprazole
  3. Omeprazole (correct answer)
  4. Calcium carbonate
Explanation: Clopidogrel is a prodrug that requires activation by the cytochrome P450 enzyme CYP2C19. Omeprazole (and its S-enantiomer, esomeprazole) is a potent inhibitor of CYP2C19, which can significantly reduce the conversion of clopidogrel to its active metabolite, thereby decreasing its antiplatelet effect and potentially leading to treatment failure (e.g., stent thrombosis). Pantoprazole is a much weaker inhibitor of CYP2C19 and is generally considered a safer alternative in this context. Famotidine (an H2-receptor antagonist) and calcium carbonate (an antacid) do not significantly interact with CYP2C19.

Question 20

A patient taking aspirin 81 mg daily for secondary prevention of cardiovascular disease also takes ibuprofen 400 mg as needed for headaches. To ensure the cardioprotective effects of aspirin are not compromised, what instruction should be provided regarding the timing of these medications?

  1. Take ibuprofen at least 30 minutes before or 8 hours after the immediate-release aspirin. (correct answer)
  2. Take both medications together with food to reduce the risk of gastrointestinal bleeding.
  3. Take aspirin at least 2 hours before or 2 hours after any dose of ibuprofen.
  4. The timing of administration is irrelevant as the two drugs act on different enzyme isoforms.
Explanation: Ibuprofen is a non-selective NSAID that can competitively and reversibly bind to the active site of COX-1. If taken before aspirin, ibuprofen can physically block aspirin from accessing its acetylation site on platelet COX-1, thereby antagonizing its irreversible antiplatelet effect. To avoid this, immediate-release aspirin should be taken at least 30 minutes before ibuprofen, allowing the aspirin to bind irreversibly first. Alternatively, if ibuprofen is taken first, one must wait at least 8 hours for the reversible inhibition by ibuprofen to wane before taking aspirin. Taking them together (B) is the worst-case scenario for the interaction. The drugs act on the same enzyme, COX-1 (D is incorrect).